Tyrosine kinase inhibitors (TKIs) targeting the ABL and BCR::ABL1 adenosine triphosphate (ATP) binding sites have significantly extended the lives of patients with chronic myeloid leukemia (CML) [1–5]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.